EA015514B1 - Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства - Google Patents

Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства Download PDF

Info

Publication number
EA015514B1
EA015514B1 EA200870086A EA200870086A EA015514B1 EA 015514 B1 EA015514 B1 EA 015514B1 EA 200870086 A EA200870086 A EA 200870086A EA 200870086 A EA200870086 A EA 200870086A EA 015514 B1 EA015514 B1 EA 015514B1
Authority
EA
Eurasian Patent Office
Prior art keywords
dihydrobenzo
group
compound
hydrogen
integer
Prior art date
Application number
EA200870086A
Other languages
English (en)
Russian (ru)
Other versions
EA200870086A1 (ru
Inventor
Вирджиния Л. Смит-Свинтоски
Аллен Б. Рейтц
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of EA200870086A1 publication Critical patent/EA200870086A1/ru
Publication of EA015514B1 publication Critical patent/EA015514B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EA200870086A 2005-12-19 2006-12-19 Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства EA015514B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75149305P 2005-12-19 2005-12-19
US11/612,222 US8937096B2 (en) 2005-12-19 2006-12-18 Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
PCT/US2006/048448 WO2007075695A2 (fr) 2005-12-19 2006-12-19 Utilisation de derives de sulfamide heterocyclique benzo-fusionne pour le traitement de la manie et du trouble bipolaire

Publications (2)

Publication Number Publication Date
EA200870086A1 EA200870086A1 (ru) 2008-12-30
EA015514B1 true EA015514B1 (ru) 2011-08-30

Family

ID=38007127

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870086A EA015514B1 (ru) 2005-12-19 2006-12-19 Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства

Country Status (25)

Country Link
US (1) US8937096B2 (fr)
EP (1) EP1968573B1 (fr)
JP (1) JP5190372B2 (fr)
KR (1) KR20080085878A (fr)
CN (1) CN101370495B (fr)
AT (1) ATE501718T1 (fr)
AU (1) AU2006331857B2 (fr)
BR (1) BRPI0620085A2 (fr)
CA (1) CA2634255C (fr)
CR (1) CR10166A (fr)
CY (1) CY1111519T1 (fr)
DE (1) DE602006020775D1 (fr)
EA (1) EA015514B1 (fr)
HK (1) HK1124546A1 (fr)
HR (1) HRP20110384T1 (fr)
IL (1) IL192181A0 (fr)
MY (1) MY147643A (fr)
NO (1) NO20083032L (fr)
NZ (1) NZ569104A (fr)
PL (1) PL1968573T3 (fr)
PT (1) PT1968573E (fr)
RS (1) RS51790B (fr)
SI (1) SI1968573T1 (fr)
SV (1) SV2008002958A (fr)
WO (1) WO2007075695A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AU2006249577A1 (en) * 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
TW200812573A (en) * 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
CA2688125A1 (fr) 2007-05-02 2008-11-13 The Mclean Hospital Corporation Procedes et compositions pour therapie par remplacement des mitochondries
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
WO2009133110A1 (fr) * 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulateurs de la neurotransmission de la dopamine
WO2009133109A1 (fr) * 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulateurs de la neurotransmission de la dopamine
CA2722978A1 (fr) * 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulateurs de la neurotransmission de la dopamine
BRPI0915890A2 (pt) 2008-06-23 2015-11-03 Janssen Pharmaceutica Nv forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CA2850513A1 (fr) 2011-09-29 2013-04-04 Janssen Pharmaceutica Nv Procede de preparation de derives de sulfamides
EP2760852A1 (fr) 2011-09-29 2014-08-06 Janssen Pharmaceutica, N.V. Procédé amélioré de préparation de dérivés de sulfamides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753693A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2527861A (en) 1948-05-07 1950-10-31 Monsanto Chemicals Mono alkyl sulfamides
BE636655A (fr) 1962-09-14
DE1211166B (de) 1962-11-20 1966-02-24 Ciba Geigy Verfahren zur Herstellung neuer Sulfamide
US3318952A (en) 1964-01-22 1967-05-09 Sandoz Ag Dibenzylsulfamides
US3320314A (en) 1964-01-22 1967-05-16 Sandoz Ag Chlorobenzyl sulfamides
US3383414A (en) 1964-08-26 1968-05-14 Sandoz Ag Benzocycloalkyl sulfamides
DE1542785A1 (de) 1965-07-24 1970-05-06 Bayer Ag Insekten- und milbenabweisende Mittel
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3621096A (en) 1969-04-03 1971-11-16 Univ North Carolina Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone
DE2022370A1 (de) 1970-05-08 1971-12-02 Bayer Ag N-Fluordichlormethylthio-sulfamidsaeure-Derivate,Verfahren zu ihrer Herstellung und ihre mikrobizide und fungizide Verwendung
US5212326A (en) 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
FR2479825A1 (fr) 1980-04-04 1981-10-09 Fabre Sa Pierre Benzodioxanne 1,4 methoxy-2 propanolamines, leur preparation et leur application en tant que medicaments
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
GB8908085D0 (en) 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5238945A (en) 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
US5273993A (en) 1989-06-12 1993-12-28 A. H. Robins Company, Incorporated Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
US5192785A (en) 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5189179A (en) 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
CA2054339C (fr) 1990-11-02 2002-12-24 Francesco G. Salituro Derives du 3-amidoindolyl
GB9026998D0 (en) 1990-12-12 1991-01-30 Glaxo Group Ltd Medicaments
US5120758A (en) 1991-02-08 1992-06-09 Ciba-Geigy Corporation Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors
GB9104890D0 (en) 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
IL103172A (en) 1991-09-19 1997-01-10 Mcneilab Inc Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol
US5242942A (en) 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5258402A (en) 1992-06-11 1993-11-02 Mcneil-Ppc, Inc. Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
CA2179733C (fr) 1993-12-23 2007-03-27 Michael J. Costanzo Sulfamates de pseudofructopyranose anticonvulsifs
GB9417532D0 (en) 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
DE69614835T2 (de) 1995-02-15 2002-04-25 Annovis, Inc. Alkylcarboxy-aminosäure modulatoren für den kainat-rezeptor
JP3235448B2 (ja) 1995-03-24 2001-12-04 ダイソー株式会社 １，４−ベンゾジオキサン誘導体の製法
US5998380A (en) 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
WO1997019919A1 (fr) 1995-11-30 1997-06-05 C & C Research Laboratories Derives de sulfamides
WO1997019682A1 (fr) 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Derives aryle sulfonamide et sulfamide, et leurs utilisations
WO1997035584A1 (fr) 1996-03-25 1997-10-02 Eli Lilly And Company Procede de traitement de la douleur
AU3501697A (en) 1996-06-28 1998-01-21 Ortho Pharmaceutical Corporation Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
ATE224189T1 (de) 1996-06-28 2002-10-15 Ortho Mcneil Pharm Inc Antikonvulsive sulfamatderivate zur behandlung von fettleibigkeit
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
DE69717281T2 (de) 1996-08-14 2003-09-04 G.D. Searle & Co., Chicago Kristalline form von 4-[5-methyl-3-phenylisoxazol-4-yl]benzolsulfonamid
CA2264182A1 (fr) 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsivant renfermant une composition pour traiter la douleur neurogene
RU2175868C2 (ru) 1996-10-08 2001-11-20 Орто-Макнейл Фармасьютикал, Инк. Производные, обладающие противосудорожным действием, пригодные для лечения невропатической боли
US20020015713A1 (en) 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US5760007A (en) 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
US5935933A (en) 1997-07-16 1999-08-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating neuropathic pain
WO1999008669A1 (fr) 1997-08-15 1999-02-25 Carolyn Ann Fairbanks Agmatine utilisee comme traitement de la douleur neuropathique
GB9803536D0 (en) 1998-02-19 1998-04-15 Black James Foundation Histamine H,receptor ligands
UA65607C2 (uk) 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
DK72798A (da) 1998-05-28 1998-05-28 Novo Nordisk As Treatment of GABA-uptake related disorders
CZ20004280A3 (cs) 1998-05-29 2001-09-12 Eli Lilly And Company Lék pro léčbu bipolárních poruch a farmaceutický prostředek
JP2002519373A (ja) 1998-07-02 2002-07-02 エーザイ株式会社 製薬組成物及びそれらの使用
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
DE60015070T2 (de) 1999-01-19 2006-01-05 Ortho-Mcneil Pharmaceutical, Inc. Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
AU3582600A (en) 1999-01-21 2000-08-07 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating transformed migraine
GB9903784D0 (en) 1999-02-18 1999-04-14 Lilly Co Eli Pharmaceutical compounds
DK1158973T3 (da) 1999-02-24 2005-05-30 Univ Cincinnati Anvendelse af sulfamatderivater til behandling af impulskontrolafvigelser
WO2000054588A1 (fr) 1999-03-15 2000-09-21 John Claude Krusz Traitement de maux de tete aigus et de douleur chronique au moyen de medicaments anesthesiques rapidement evacues dans des doses subanesthesiques
MXPA01010223A (es) 1999-04-08 2002-09-18 Johnson & Johnson Derivados anticonvulsivos utiles para mantener la perdida de peso.
CA2369095C (fr) 1999-04-08 2006-07-25 Ortho-Mcneil Pharmaceutical, Inc. Derives anticonvulsivants utiles pour traiter des etats neurodegeneratifs chroniques
NZ514810A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in lowering lipids
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
WO2000066109A2 (fr) 1999-05-04 2000-11-09 Edwards Keith R Valproate administre par voie intraveineuse dans les soins actifs des migraines
EP1187603B1 (fr) 1999-06-14 2007-08-08 Vivus, Inc. Therapie combinee permettant de perdre du poids et de traiter l'obesite
WO2001013904A2 (fr) 1999-08-20 2001-03-01 Ortho-Mcneil Pharmaceutical, Inc. Composition contenant du tramadol et un medicament anticonvulsant
FR2803848B1 (fr) 2000-01-19 2002-02-15 Adir Nouveaux derives de benzenesulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6322503B1 (en) 2000-02-17 2001-11-27 G. Roger Sparhawk, Jr. Method of diagnosing, tracking, and treating depression
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
WO2002003984A2 (fr) 2000-07-07 2002-01-17 Ortho-Mcneil Pharmaceutical, Inc. Derives anti-convulsion utiles au niveau de la prevention du developpement du diabete sucre type ii et du syndrome x
DE10035227A1 (de) 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
WO2002009694A1 (fr) 2000-08-02 2002-02-07 Ortho-Mcneil Pharmaceutical, Inc. Derives anticonvulsivants utilises dans le traitement de la depression
AR034160A1 (es) 2000-09-30 2004-02-04 Gruenenthal Gmbh Sulfonilguanidinas, medicamentos que contienen estos compuestos y el uso de sulfonilguanidinas
US7256184B2 (en) 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
AU2002240235B2 (en) 2001-01-30 2006-07-06 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
WO2002089785A1 (fr) 2001-05-07 2002-11-14 Smithkline Beecham Corporation Sulfonamides
CA2448160A1 (fr) 2001-05-25 2002-12-05 Queen's University At Kingston Beta-acides amines heterocycliques et leur utilisation en tant qu'agents anti-epileptogenes
US20030100594A1 (en) 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
RU2246727C2 (ru) 2003-02-12 2005-02-20 Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева (НИПИ) Способ диагностики доклинической стадии эпилепсии
RU2226357C1 (ru) 2003-02-12 2004-04-10 Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М.Бехтерева Способ диагностики эпилепсии у пациентов с доклинической стадией болезни
WO2004092116A1 (fr) 2003-04-10 2004-10-28 Amgen, Inc. Composes bicycliques presentant une affinite pour les recepteurs de la bradykinine et compositions pharmaceutiques en contenant
AU2003223634A1 (en) 2003-04-16 2004-11-26 Siegfried B. Christensen Iv Peptide deformylase inhibitors
JPWO2004093912A1 (ja) 2003-04-23 2006-07-13 協和醗酵工業株式会社 好中球性炎症疾患の予防および／または治療剤
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
US6949518B1 (en) 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
EP1664011A4 (fr) 2003-09-02 2009-02-25 Merck & Co Inc Compositions ophtalmiques pour le traitement de l'hypertension oculaire
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
JP5026963B2 (ja) 2004-06-22 2012-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド カルシウムチャネル調整用の複素環誘導体
KR101261305B1 (ko) 2004-07-28 2013-05-08 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로의 치환된 인돌릴알킬 아미노 유도체
US20060276528A1 (en) 2004-08-24 2006-12-07 Abdel-Magid Ahmed F Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
ATE400565T1 (de) 2004-08-24 2008-07-15 Janssen Pharmaceutica Nv Als antikonvulsive mittel geeignete neue benzokondensierte heteroarylsulfamidderivate
CN101218223A (zh) 2005-04-22 2008-07-09 惠氏公司 苯并二烷和苯并二氧戊环衍生物及其应用
AU2006249577A1 (en) 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US20070155824A1 (en) 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US20070155823A1 (en) 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155827A1 (en) 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070191452A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain
US20070191474A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
TW200738669A (en) 2006-02-22 2007-10-16 Janssen Pharmaceutica Nv Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide
TW200812573A (en) 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
TW200812574A (en) 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
CA2711466A1 (fr) 2008-01-07 2009-07-16 Janssen Pharmaceutica N.V. Procede de fabrication de derives de sulfamide
US20090247617A1 (en) 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247618A1 (en) 2008-03-26 2009-10-01 Ballentine Scott A Process for preparation of benzo-fused heteroaryl derivatives
KR20100126535A (ko) 2008-03-26 2010-12-01 얀센 파마슈티카 엔.브이. 벤조-융합된 헤테로아릴 설파메이트의 제조방법 및 ｎ-(((2ｓ)-6-클로로-2,3-다이하이드로-1,4-벤조다이옥신-2-일)메틸-설파미드의 결정형
MX2010010597A (es) 2008-03-26 2010-10-25 Janssen Pharmaceutica Nv Procesos para la preparacion de derivados de dioxina benzofusionados.
BRPI0915890A2 (pt) 2008-06-23 2015-11-03 Janssen Pharmaceutica Nv forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753693A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BESAG F.M.C.: "BEHAVIOURAL EFFECTS OF THE NEW ANTICONVULSANTS", DRUG SAFETY, ADIS PRESS, AUCKLAND, NZ, vol. 24, no. 7, 2001, pages 513-536, XP001030116, ISSN: 0114-5916, 5. Topiramate *
MARYANOFF B.E. ET AL.: "Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform", JOURNAL OF MEDICINAL CHEMISTRY, 24 MAR. 2005, UNITED STATES, vol. 48, no. 6, 24 March 2005 (2005-03-24), pages 1941-1947, XP002431411, ISSN: 0022-2623, compounds 15, 17 *

Also Published As

Publication number Publication date
CR10166A (es) 2008-11-24
IL192181A0 (en) 2009-08-03
WO2007075695A2 (fr) 2007-07-05
NZ569104A (en) 2011-04-29
RS51790B (en) 2011-12-31
US8937096B2 (en) 2015-01-20
HK1124546A1 (en) 2009-07-17
PT1968573E (pt) 2011-04-29
CY1111519T1 (el) 2015-08-05
ATE501718T1 (de) 2011-04-15
JP5190372B2 (ja) 2013-04-24
DE602006020775D1 (de) 2011-04-28
CA2634255A1 (fr) 2007-07-05
PL1968573T3 (pl) 2011-07-29
SI1968573T1 (sl) 2011-06-30
CN101370495B (zh) 2011-10-19
EP1968573B1 (fr) 2011-03-16
CA2634255C (fr) 2014-08-05
KR20080085878A (ko) 2008-09-24
EP1968573A2 (fr) 2008-09-17
CN101370495A (zh) 2009-02-18
US20070155826A1 (en) 2007-07-05
AU2006331857B2 (en) 2013-01-10
NO20083032L (no) 2008-09-16
EA200870086A1 (ru) 2008-12-30
MY147643A (en) 2012-12-31
AU2006331857A1 (en) 2007-07-05
JP2009520030A (ja) 2009-05-21
SV2008002958A (es) 2010-01-18
WO2007075695A3 (fr) 2007-11-15
HRP20110384T1 (hr) 2011-06-30
BRPI0620085A2 (pt) 2011-11-01

Similar Documents

Publication Publication Date Title
EA015514B1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства
KR101415532B1 (ko) 우울증 치료를 위한 벤조-융합된 헤테로사이클 설파미드유도체의 용도
AU2011316225B2 (en) Combinations of serotonin receptor agonists for treatment of movement disorders
EA016302B1 (ru) Способы снятия боли с использованием бензоконденсированных гетероциклических сульфамидных производных (варианты)
KR20080089405A (ko) 신경보호제로써 벤조-융합된 헤테로사이클 설파미드유도체의 용도
AU3410200A (en) Method for the treatment of neurological or neuropsychiatric disorders
ES2267153T3 (es) Antagonistas del receptor nk-1 penetrantes del snc como agentes antidepresivos y/o antiansiedad.
WO2012163365A1 (fr) Combinaisons d'agonistes de récepteur de sérotonine pour le traitement de troubles du mouvement
US20070191450A1 (en) Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
ES2360135T3 (es) Uso de derivados de sulfamidas heterociclicos benzo-condensados para el tratamiento de la mania y el trastorno bipolar.
ES2517598T3 (es) Uso de derivados de sulfamida heterocíclica benzo - fusionada para el tratamiento de la ansiedad

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ KG MD TJ TM RU

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM